Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
This Section of Epidemiology and Psychiatric Sciences appears in each issue of the Journal to stress the role of the epidemiological approach to promote advances in the field of clinical psychopharmacology, with a particular attention to controversial findings.The ultimate aims are to help develop a more critical attitude towards the results of research studies published in the international literature, to promote original research projects with higher methodological standards, and to implement the most relevant results of research in every-day clinical practice.These contributions are written in house by the journal's editorial team or commissioned by the Section Editor (no more than 1000 words, short unstructured abstract, 4 key-words, one Table or Figure and up to ten references).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a meta-analysis of studies assessing various treatments for TRD, the rates of non-fatal suicidal behavior and suicide death were 4.66 and 0.47 per 100 patient-years, respectively [32–34].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“This observation is in line with relapse rates seen in the STAR*D study in levels 3 and 4 (Rush et al., 2006), respectively, where relapse rates in those achieving remission following the 12- to 14-week acute treatment phase were 42.”
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Self-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Self-citationFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · cited 2×
“All three short-term efficacy studies, including the two that did not show statistical significance on the primary endpoint [TRANSFORM-1 (Fedgchin et al ., 2019) and TRANSFORM-3 (Ochs-Ross et al ., 2020)] demonstrated between-group mean differences relative to the comparator (a new oral…”
Self-citationOchs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Self-citationEsketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333 · cited 11×
“Note that the FDA generally requires only short-term studies for initial approval of antidepressants; long-term studies are typically conducted after approval to support a maintenance indication (Kim et al ., 2019).”
InfluentialWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308 · cited 4×
“The two phase 3 registration trials [SUSTAIN-1 (Daly et al ., 2019); SUSTAIN-2 (Wajs et al ., 2020)] assessed the maintenance of anti-depressant effects beyond the initial acute treatment period with esketamine nasal spray in adult patients with treatment-resistant MDD (Food and Drug…”
InfluentialSelf-citationTreatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256 · cited 12×
“The safety profile of esketamine was well characterized in the clinical development programme that included 19 phase 1 studies, four phase 2 studies and six phase 3 studies in TRD.”
InfluentialMontgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121 · cited 1×
“…relative to the comparator (a new oral antidepressant plus placebo nasal spray), with regard to the change in MADRS total score, which exceeded the mean difference that is considered clinically relevant in the psychiatric literature, namely 2.0 points or higher (Montgomery and Möller, 2009).”
Influential
Cited by
Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01577-5 · Cited by 137
Self-citationGastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000510703 · Cited by 134
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
Zaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Young, A. H., Lacerda, A. L. T., et al. (2025) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf027 · Cited by 56
Self-citationBrendle, M., Ahuja, S., Valle, M. D., Moore, C., Thielking, P. D., Malone, D. C., & Robison, R. J. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0149 · Cited by 46
Ammendolia, I., Mannucci, C., Esposito, E., Calapai, G., Currò, M., Midiri, P., Mondello, C., Cardia, L., & Calapai, F. (2025) · Pharmaceuticals · doi:10.3390/ph18050702 · Cited by 8
“Moreover, according to other authors, it is very difficult to differentiate between suicidal ideation as part of depression intended as a disease with respect to suicidal ideation potentially related to lack of esketamine effectiveness or as a reaction induced by esketamine [55].”
Metadata
- Authors
- Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C.
- Affiliations
- Janssen Research & Development (United States) (US)
- Janssen Scientific Affairs (United States) (US)
- Janssen (Belgium) (BE)
- Janssen (Germany) (DE)
- Corresponding author
- Mathews, Maju
- Venue
- Epidemiology and Psychiatric Sciences
- Publisher
- Cambridge University Press (CUP)
- Published
- 2020
- Volume
- 29
- Pages
- e124-e124
- ISSN
- 2045-7960 (ISSN-L)
- 2045-7979
- PMC
- PMC7214706
- OpenAlex
- W3018458774
- Cited by
- 7
- References
- 12
- Citations by year
- 2025: 3 · 2023: 1 · 2022: 1 · 2020: 2
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Epidemiology and Psychiatric Sciences (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- clinical psychopharmacology, epidemiological approach, research-to-practice translation
- MeSH terms
- Humans, Ketamine, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui. https://app.cochat.ai/papers/10.1017/s2045796020000268
- The paper
- Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C. (2020). Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796020000268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.